RE: Excellent News20 Jun 2019 08:32
..and this is a massive step change ‘..aliRx is pleased to announce that based on its clinical results, a substantial amendment to the clinical trial protocol has received regulatory approval from the Medicines and Healthcare products Regulatory Agency ("MHRA") and the Research ethics committee (REC)
Following approval of the substantial amendment, an authoritative prostate cancer specialist, Dr Mark Linch has been appointed as Principal Investigator to the clinical trial team at University College London Hospital ("UCLH"). Dr Linch is an Honorary Senior Lecturer at University College London (UCL) Cancer Institute, where he leads the Uro-oncology Biology Group, and he is also a Consultant Medical Oncologist specialising in the treatment of prostate and bladder cancer at UCLH. Dr Rebecca Kristeleit continues with the study as Chief Investigator.’